Literature DB >> 19537841

Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery.

Gillian M Keating1.   

Abstract

Levofloxacin 0.5% ophthalmic solution (Cravit, Quixin, Oftaquix) has well established efficacy and tolerability in the treatment of external ocular infections. Levofloxacin 0.5% ophthalmic solution was generally more effective than ofloxacin 0.3% ophthalmic solution in the treatment of external ocular infections, and noninferiority was seen between levofloxacin 0.5% ophthalmic solution and both moxifloxacin 0.5% and tosufloxacin 0.3% ophthalmic solutions in the treatment of bacterial conjunctivitis. Although levofloxacin 0.5% ophthalmic solution administered in the hour prior to surgery did not reduce the incidence of endophthalmitis in patients undergoing intraocular surgery, additional data are needed to examine an optimal preoperative regimen of this antibacterial; preoperative levofloxacin 0.5% ophthalmic solution plus an iodine eyewash reduced positive culture rates in patients undergoing intraocular surgery. Levofloxacin 0.5% ophthalmic solution was well tolerated in the treatment of external ocular infections. Thus, levofloxacin 0.5% ophthalmic solution remains an important option in the treatment of bacterial conjunctivitis and other external ocular infections, as well as for perioperative use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19537841     DOI: 10.2165/00003495-200969090-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  41 in total

Review 1.  Management strategies for acute infective conjunctivitis in primary care: a systematic review.

Authors:  Peter Rose
Journal:  Expert Opin Pharmacother       Date:  2007-08       Impact factor: 3.889

Review 2.  Mechanism of fluoroquinolone action.

Authors:  K Drlica
Journal:  Curr Opin Microbiol       Date:  1999-10       Impact factor: 7.934

3.  Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration.

Authors:  Daniel P Healy; Edward J Holland; Michael L Nordlund; Steven Dunn; Christopher Chow; Richard L Lindstrom; David Hardten; Elizabeth Davis
Journal:  Cornea       Date:  2004-04       Impact factor: 2.651

4.  Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients.

Authors:  Steven J Lichtenstein; Mike Rinehart
Journal:  J AAPOS       Date:  2003-10       Impact factor: 1.220

5.  A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.

Authors:  D G Hwang; D J Schanzlin; M H Rotberg; G Foulks; M B Raizman
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

6.  The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.

Authors:  Shin Hae Park; Jeong-A Lim; Jun-Sub Choi; Kyung-A Kim; Choun-Ki Joo
Journal:  Cornea       Date:  2009-01       Impact factor: 2.651

7.  Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey.

Authors:  David F Chang; Rosa Braga-Mele; Nick Mamalis; Samuel Masket; Kevin M Miller; Louis D Nichamin; Richard B Packard; Mark Packer
Journal:  J Cataract Refract Surg       Date:  2007-10       Impact factor: 3.351

8.  Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors.

Authors: 
Journal:  J Cataract Refract Surg       Date:  2007-06       Impact factor: 3.351

9.  United Kingdom survey of antibiotic prophylaxis practice after publication of the ESCRS Endophthalmitis Study.

Authors:  Daniel M Gore; Romesh I Angunawela; Brian C Little
Journal:  J Cataract Refract Surg       Date:  2009-04       Impact factor: 3.351

10.  Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.

Authors:  M Yamada; J Yoshida; S Hatou; T Yoshida; Y Minagawa
Journal:  Br J Ophthalmol       Date:  2008-05-06       Impact factor: 4.638

View more
  3 in total

1.  Drug delivery to the posterior segment of the eye for pharmacologic therapy.

Authors:  Shalin S Shah; Lori Vidal Denham; Jasmine R Elison; Partha S Bhattacharjee; Christian Clement; Tashfin Huq; James M Hill
Journal:  Expert Rev Ophthalmol       Date:  2010-02-01

2.  Fixed-Combination Eye Drops Based on Fluorometholone Nanoparticles and Bromfenac/Levofloxacin Solution Improve Drug Corneal Penetration.

Authors:  Hiroko Otake; Ryoka Goto; Fumihiko Ogata; Takumi Isaka; Naohito Kawasaki; Shinichiro Kobayakawa; Toru Matsunaga; Noriaki Nagai
Journal:  Int J Nanomedicine       Date:  2021-08-10

Review 3.  Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.

Authors:  Ioana-Andreea Lungu; Octavia-Laura Moldovan; Victoria Biriș; Aura Rusu
Journal:  Pharmaceutics       Date:  2022-08-22       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.